Biotech
Thursday May 8
Pozen's revenue forecast tops Wall Street expectations
Pozen foresees better sales for its recently approved migraine drug than Wall Street analysts. via Local Tech Wire
Posted by roboblogger
Full Story: Local Tech Wire
Complete Coverage: 5 stories
- News Observer - Pozen reports wider loss
- Triangle Business Journal - Trials costs inflate Pozen's loss
- Zacks Analyst Blog - Buy-Rated Pozen Worth the Risks
- 2 more...
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Nastech plans to change its name | 21 min | JIMMY T | 1 |
| Surfer's slaying reveals gang fears | 6 hr | UUUH | 9 |
| Holocaust survivor runs for melanoma awareness | 7 hr | Duece | 6 |
| "They are as much a gang as any fraternity." | 7 hr | Bird Rock Bu... | 2 |
| Surfer Slaying Suspects To Challenge Gang Alleg... | 7 hr | Aslueth | 4 |
| Pfizer to close Terre Haute plant | 10 hr | Viagra anyone | 3 |
| Report: 1 in 4 teen girls has STD | 10 hr | KarSon Calif... | 12 |
